Comparative Pharmacology
Head-to-head clinical analysis: HALOTEX versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTEX versus NYSTEX.
HALOTEX vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal